JP2018535255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535255A5 JP2018535255A5 JP2018541548A JP2018541548A JP2018535255A5 JP 2018535255 A5 JP2018535255 A5 JP 2018535255A5 JP 2018541548 A JP2018541548 A JP 2018541548A JP 2018541548 A JP2018541548 A JP 2018541548A JP 2018535255 A5 JP2018535255 A5 JP 2018535255A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- formula
- cryptophycin
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 229930188224 Cryptophycin Natural products 0.000 claims 23
- 108010006226 cryptophycin Proteins 0.000 claims 23
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 claims 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 21
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical class C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 claims 16
- -1 —OH Chemical group 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- JFCBEFFZEOHJDG-MLWJPKLSSA-N (2s)-2,6-diamino-7-oxooctanoic acid Chemical compound CC(=O)C(N)CCC[C@H](N)C(O)=O JFCBEFFZEOHJDG-MLWJPKLSSA-N 0.000 claims 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000003636 chemical group Chemical group 0.000 claims 4
- 125000000524 functional group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003172 aldehyde group Chemical group 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 235000013477 citrulline Nutrition 0.000 claims 2
- 229960002173 citrulline Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 claims 1
- WAMWSIDTKSNDCU-UHFFFAOYSA-N 2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)C(N)C1CCCCC1 WAMWSIDTKSNDCU-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims 1
- 238000006942 Corey-Chaykovsky ring formation reaction Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 229940000635 beta-alanine Drugs 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 150000002576 ketones Chemical group 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000005710 macrocyclization reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 238000005897 peptide coupling reaction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306751 | 2015-11-05 | ||
| EP15306751.7 | 2015-11-05 | ||
| PCT/EP2016/076603 WO2017076998A1 (en) | 2015-11-05 | 2016-11-03 | Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535255A JP2018535255A (ja) | 2018-11-29 |
| JP2018535255A5 true JP2018535255A5 (enExample) | 2019-12-05 |
| JP6929292B2 JP6929292B2 (ja) | 2021-09-01 |
Family
ID=54476881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541548A Active JP6929292B2 (ja) | 2015-11-05 | 2016-11-03 | 新規なクリプトフィシン化合物およびコンジュゲート、これらの製造およびこれらの治療用途 |
Country Status (35)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI714661B (zh) | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| AU2018265333C1 (en) * | 2017-05-10 | 2025-04-24 | Sanofi | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation |
| CN108107103B (zh) * | 2017-12-14 | 2020-10-16 | 华中师范大学 | 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法 |
| WO2020181165A1 (en) | 2019-03-07 | 2020-09-10 | Conatus Pharmaceuticals Inc. | Caspase inhibitors and methods of use thereof |
| WO2021067460A1 (en) | 2019-09-30 | 2021-04-08 | The Regents Of The University Ofmichigan | Biocatalytic synthesis of cryptophycin anticancer agents |
| EP4046996A1 (en) | 2021-02-19 | 2022-08-24 | Universität Bielefeld | Cryptophycin compounds and conjugates thereof |
| CN118742328A (zh) | 2022-02-22 | 2024-10-01 | 阿拉里斯生物技术股份公司 | 包含两个或更多个有效载荷的肽接头 |
| EP4495108A1 (en) | 2023-07-17 | 2025-01-22 | Basf Se | 3-[2-(2-oxo-1,3-dioxolan-4-ylidene)ethoxy]propanoic acid derivatives as precursors of monomers in polymerisations |
| EP4495105A1 (en) | 2023-07-17 | 2025-01-22 | Basf Se | 3-(4-hydroxybut-2-ynoxy)propanoic acid ester, amide and nitrile derivatives as corrosion protection agents |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2179490A1 (en) * | 1993-12-21 | 1995-06-29 | Trimurtulu Golakoti | New cryptophycins |
| US20020128185A1 (en) * | 1998-02-25 | 2002-09-12 | Chuan Shih | Pharmaceutical compounds |
| US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| WO2007127440A2 (en) | 2006-04-27 | 2007-11-08 | Intezyne Technologies, Inc. | Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
| EA020324B1 (ru) | 2006-07-18 | 2014-10-30 | Санофи-Авентис | АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ |
| FR2947269B1 (fr) * | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| TWI714661B (zh) * | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
-
2016
- 2016-11-02 TW TW105135522A patent/TWI714661B/zh active
- 2016-11-03 EP EP16791017.3A patent/EP3371179B1/en active Active
- 2016-11-03 AU AU2016347724A patent/AU2016347724B2/en active Active
- 2016-11-03 HR HRP20191729 patent/HRP20191729T1/hr unknown
- 2016-11-03 US US15/768,792 patent/US10941139B2/en active Active
- 2016-11-03 TN TNP/2018/000131A patent/TN2018000131A1/en unknown
- 2016-11-03 WO PCT/EP2016/076603 patent/WO2017076998A1/en not_active Ceased
- 2016-11-03 SI SI201630418T patent/SI3371179T1/sl unknown
- 2016-11-03 PL PL16791017T patent/PL3371179T3/pl unknown
- 2016-11-03 MX MX2018005379A patent/MX374535B/es active IP Right Grant
- 2016-11-03 MY MYPI2018701424A patent/MY189448A/en unknown
- 2016-11-03 HU HUE16791017A patent/HUE046033T2/hu unknown
- 2016-11-03 CR CR20180256A patent/CR20180256A/es unknown
- 2016-11-03 MA MA43160A patent/MA43160B1/fr unknown
- 2016-11-03 CN CN201680064372.8A patent/CN108349960B/zh active Active
- 2016-11-03 ES ES16791017T patent/ES2755101T3/es active Active
- 2016-11-03 LT LT16791017T patent/LT3371179T/lt unknown
- 2016-11-03 KR KR1020187015447A patent/KR102822076B1/ko active Active
- 2016-11-03 HK HK18115834.8A patent/HK1256754B/en unknown
- 2016-11-03 SG SG11201803181SA patent/SG11201803181SA/en unknown
- 2016-11-03 JP JP2018541548A patent/JP6929292B2/ja active Active
- 2016-11-03 RS RS20191429A patent/RS59498B1/sr unknown
- 2016-11-03 DK DK16791017T patent/DK3371179T3/da active
- 2016-11-03 PT PT167910173T patent/PT3371179T/pt unknown
- 2016-11-03 CA CA3003085A patent/CA3003085A1/en active Pending
- 2016-11-03 EA EA201890898A patent/EA035625B1/ru not_active IP Right Cessation
- 2016-11-04 AR ARP160103379A patent/AR106604A1/es not_active Application Discontinuation
- 2016-11-04 UY UY0001036979A patent/UY36979A/es not_active Application Discontinuation
-
2018
- 2018-04-10 ZA ZA2018/02322A patent/ZA201802322B/en unknown
- 2018-04-20 PH PH12018500852A patent/PH12018500852B1/en unknown
- 2018-04-27 CO CONC2018/0004581A patent/CO2018004581A2/es unknown
- 2018-05-01 IL IL259067A patent/IL259067B/en unknown
- 2018-05-03 EC ECIEPI201834035A patent/ECSP18034035A/es unknown
- 2018-05-04 CL CL2018001210A patent/CL2018001210A1/es unknown
-
2019
- 2019-11-06 CY CY20191101166T patent/CY1122441T1/el unknown
-
2020
- 2020-12-10 US US17/118,204 patent/US20210163458A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191729T1 (hr) | Novi spojevi i konjugati kriptoficina, njihova priprava i njihova terapeutska uporaba | |
| CN102597773B (zh) | 功能性分子的可逆的共价连接 | |
| KR102345175B1 (ko) | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 | |
| CN108465112B (zh) | 自稳定接头偶联物 | |
| US9248173B2 (en) | WT1 antigen peptide conjugate vaccine | |
| KR20200083605A (ko) | 프로그램가능한 중합체성 약물 | |
| JP2021527040A (ja) | カンプトテシンコンジュゲート | |
| TWI778059B (zh) | 新穎之肽連接子與念珠藻素接合物，其製備方法及治療之用途 | |
| WO2019201123A1 (zh) | 一种多功能化合物、其制备方法及其在医药上的应用 | |
| CN108779127A (zh) | 美登素类化合物衍生物、其偶联物和使用方法 | |
| KR20210125094A (ko) | 비스-링키지를 사용한 세포독성 약물의 접합 | |
| JP2018503639A5 (enExample) | ||
| JP2020519610A5 (enExample) | ||
| CN108367043A (zh) | 季铵化的微管溶素化合物的缀合物 | |
| EP3082877A2 (en) | Cytotoxic peptides and conjugates thereof | |
| JP7706668B2 (ja) | 抗体－薬物コンジュゲート及びそれらの使用 | |
| WO2022199237A1 (zh) | 修饰的氨基酸及其在adc中的应用 | |
| JP2020533308A (ja) | チューブリシンおよびそれらの中間体の調製のためのプロセス | |
| CN116137818B (zh) | 对-氨基-苄基接头、其制备方法及其在缀合物中的用途 | |
| JP2008531475A (ja) | アミノチオール含有分子をビヒクルと複合化する方法 | |
| KR20260060354A (ko) | 분자 접착제 분해제를 기반으로 하는 항체-약물 접합체 및 그의 용도 | |
| EP4608454A1 (en) | Self-hydrolyzing maleimides for bioconjugation | |
| WO2024077212A2 (en) | Site-specific covalent ligation of human serum albumin | |
| JP2025541189A (ja) | 腫瘍疾患および／または感染症の併用療法用キット |